Hikma Pharmaceuticals Plc Total Voting Rights (4943Q)
February 29 2016 - 8:47AM
UK Regulatory
TIDMHIK
RNS Number : 4943Q
Hikma Pharmaceuticals Plc
29 February 2016
Voting Rights and Capital and UK Takeover Code
London, 29 February 2016 - Further to the announcement dated 29
February 2016 by Hikma Pharmaceuticals PLC ("Hikma" or the
"Company") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) relating to
the completion of the acquisition by the Company of Roxane
Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from
Boehringer Ingelheim Corporation (the "Acquisition"), the Company
wishes to notify the market of the following:
As at 29 February 2016, the Company's capital consists of
239,385,501 ordinary shares with voting rights. There are nil
shares held in treasury.
Pursuant to the shareholders' agreement entered into at
completion of the Acquisition between the Company, Boehringer
Ingelheim International GmbH and Boehringer Ingelheim Corporation,
the Boehringer Ingelheim group is only entitled to exercise voting
rights attaching to 28,500,000 of the 40,000,000 ordinary shares in
the Company that it currently holds, as more fully described in the
combined prospectus and circular relating to the Acquisition.
However, the full 40,000,000 ordinary shares held by the Boehringer
Ingelheim group should be taken into account for the purposes of
the FCA's Disclosure and Transparency Rules.
Accordingly, the above figure of 239,385,501 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure and Transparency Rules.
Shareholders should also note that the full 40,000,000 ordinary
shares held by the Boehringer Ingelheim group are regarded as
having voting rights for the purposes of the UK Takeover Code.
Accordingly, shareholders (including members of the Boehringer
Ingelheim group) should use the above figure of 239,385,501 as the
denominator for the calculations by which they would determine
their interest in shares which carry voting rights. For the
purposes of Rule 9 of the UK Takeover Code, (a) the Boehringer
Ingelheim group is regarded as being interested in shares carrying
approximately 16.71 per cent. of the voting rights of Hikma and (b)
Darhold Limited and the Concert Party are regarded as being
interested in shares carrying approximately 26.31 per cent. of the
voting rights of Hikma.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs +44 20 7399 2760
Company Secretary
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $278 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREADANALXKEFF
(END) Dow Jones Newswires
February 29, 2016 08:47 ET (13:47 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024